This suggests that during chronic inflammation conditions like GVHD, IL-22 may play a role that promotes disease progression rather than amelioration, fezakinumab treatment has been shown to improve clinical disease scores in patients with atopic dermatitis, particularly among those with elevated serum IL-22 levels [182]. This evidence concerns the gene IL22 and graft versus host disease.